ZyVersa Therapeutics, Inc. financial data

Symbol
ZVSA on OTC
Location
Weston, FL
Fiscal year end
31 December
Latest financial report
10-Q - Q3 2025 - 19 Nov 2025

Key Ratios

Label TTM Value / Value Unit Change %
Current Ratio 11% % -37%
Debt-to-equity 465% % 295%
Return On Equity -933% % -315%
Return On Assets -165% % -60%

Shares

Label TTM Value / Value Unit Change %
Entity Common Stock, Shares Outstanding 8,095,921 shares
Common Stock, Shares, Outstanding 8,095,921 shares 654%
Entity Public Float $3,100,000 USD -45%
Common Stock, Value, Issued $809 USD 656%
Weighted Average Number of Shares Outstanding, Basic 7,740,678 shares 683%
Weighted Average Number of Shares Outstanding, Diluted 7,740,678 shares 683%

Income Statement

Label TTM Value / Value Unit Change %
Research and Development Expense $1,155,112 USD -40%
General and Administrative Expense $6,424,417 USD -17%
Operating Income (Loss) $26,227,432 USD -20%
Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling Interest $20,657,218 USD -760%
Income Tax Expense (Benefit) $851,659 USD
Net Income (Loss) Attributable to Parent $25,695,505 USD -20%
Earnings Per Share, Basic -1 USD/shares -100%
Earnings Per Share, Diluted -1 USD/shares -100%

Balance Sheet

Label TTM Value / Value Unit Change %
Assets, Current $995,533 USD 155%
Property, Plant and Equipment, Net $1,733 USD -86%
Other Assets, Noncurrent $18,647,903 USD 0%
Assets $1,040,260 USD -95%
Accounts Payable, Current $9,805,129 USD 5.6%
Accrued Liabilities, Current $2,960,698 USD 31%
Liabilities, Current $12,765,827 USD 11%
Deferred Income Tax Liabilities, Net $851,659 USD -0.35%
Liabilities $12,765,827 USD 3%
Retained Earnings (Accumulated Deficit) $136,906,365 USD -23%
Stockholders' Equity Attributable to Parent $11,725,567 USD -267%
Liabilities and Equity $1,040,260 USD -95%

Popular Metrics

Label TTM Value / Value Unit Change %
Net Cash Provided by (Used in) Operating Activities $1,772,052 USD 53%
Net Cash Provided by (Used in) Financing Activities $1,852,660 USD -31%
Common Stock, Shares Authorized 250,000,000 shares 0%
Common Stock, Shares, Issued 8,095,928 shares 654%
Common Stock, Par or Stated Value Per Share 0 USD/shares 0%
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate Effect $80,608 USD
Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents $527,978 USD 330%
Deferred Tax Assets, Valuation Allowance $15,953,288 USD 13%
Deferred Tax Assets, Gross $19,768,888 USD 11%
Property, Plant and Equipment, Gross $52,000 USD 0%
Deferred Tax Assets, Operating Loss Carryforwards $12,544,318 USD 26%
Preferred Stock, Shares Authorized 1,000,000 shares 0%
Additional Paid in Capital $125,187,156 USD 5.9%
Deferred Tax Assets, Net of Valuation Allowance $3,815,600 USD 0.62%
Share-based Payment Arrangement, Expense $366,143 USD -56%
Preferred Stock, Par or Stated Value Per Share 0 USD/shares 0%